South Africa’s Biovac to start manufacturing Pfizer-BioNTech vaccine for COVID-19 in early 2022

KIGALI, Rwanda, Dec 6 (Reuters) – South Africa’s Biovac Institute will begin manufacturing Pfizer-BioNTech’s COVID-19 vaccine early next year after receiving the drug substance from facilities in Europe, an executive from the the pharmaceutical.

The agreement for the final stages of manufacturing, where the product is processed and placed in vials, will make Biovac one of the few companies that process injections for COVID-19 in Africa, where many countries have difficulty accessing enough doses.

“We expect the Cape Town facility to join our supply chain later this year, with a few weeks left,” said Patrick van der Loo, Pfizer Regional President for Africa and the Middle East.

“Biovac will source the drug from facilities in Europe and manufacturing of the finished doses will begin in early 2022,” he added.

The company explained that Pfizer is exploring ways to bring other partners into its supply chain to accelerate access to its COVID-19 injection.

(Reporting by Clement Uwiringiyimana and Estelle Shirbon. Written by Alexander Winning. Edited in Spanish by Javier Leira)

Article Source